首页> 外文期刊>Medicine. >Clinical outcomes and time to recurrence of phototherapeutic keratectomy in Japan
【24h】

Clinical outcomes and time to recurrence of phototherapeutic keratectomy in Japan

机译:日本光治疗角膜切除术复发的临床结果和时间

获取原文
获取外文期刊封面目录资料

摘要

To assess the indications, outcomes and time to recurrence of phototherapeutic keratectomy (PTK) for anterior corneal pathology. This study involved 714 eyes of 477 consecutive patients (mean age: 66.0 ± 15.2 years; range: 6–101 years) who underwent PTK as the initial surgical intervention for an anterior corneal pathology. In case of each patient, the cornea treated by PTK, followed up by slit-lamp examination and corrected distance visual acuity (CDVA) testing. Main outcome measures included Slit-lamp findings (1), CDVA (2), patients’ complaints (3). The mean follow-up period was 44.0 ± 38.8 months (range: 1–156 months). We treated 376 granular corneal dystrophy (GCD) eyes, 238 band keratopathy (BK) eyes, 23 epithelium attachment disorder eyes, 16 gelatinous drop-like corneal dystrophy (GDLD) eyes, 13 lattice corneal dystrophy (LCD) eyes, and 48 eyes with other corneal diseases. The CDVA significantly improved from LogMAR 0.65 ± 0.61 pre PTK to LogMAR 0.26 ± 0.39 post PTK. A 2 or more lines increase of CDVA was observed in GCD eyes (67.8%), BK eyes (49.2%), epithelium attachment disorder eyes (57.1%), GDLD eyes (87.5%), LCD eyes (76.9%), and other corneal disease eyes (60.4%). The recurrence of BK was rare. GCD recurred slowly. Epithelium attachment disorder eyes remitted simultaneously, and recurred comparatively faster. PTK was proved to be a successful therapy for all 6 corneal disease categories. Disease recurrence after PTK differed among the diseases, and surgeons should recognize the different rates of disease recurrence after PTK surgery.
机译:评估前视抗角膜病理学的光治疗性角膜切除术(PTK)的适应症,结果和时间。这项研究涉及477名连续患者的714只眼睛(平均:66.0±15.2岁;范围:6-101岁),他们接受了PTK作为前角膜病理学的初始手术干预。在每位患者的情况下,通过PTK处理的角膜,通过狭缝灯检查和矫正距离视力(CDVA)测试进行跟进。主要结果措施包括狭缝灯调查结果(1),CDVA(2),患者投诉(3)。平均随访期为44.0±38.8个月(范围:1-156个月)。我们治疗了376个粒状角膜营养不良(GCD)眼睛,238频段角膜病(BK)眼睛,23个上皮附着障碍眼睛,16个凝胶状滴的角膜营养不良症(GDLD)眼睛,13个格角膜营养不良(LCD)眼睛,48只眼睛其他角膜疾病。 CDVA从Logmar 0.65±0.61 pre PTK显着改善,以logmar 0.26±0.39 PTK。在GCD眼睛(67.8%),BK眼睛(49.2%),上皮附着障碍的眼睛(57.1%),GDLD眼睛(87.5%),液晶眼(76.9%)等角膜疾病的眼睛(60.4%)。 BK的复发很少见。 GCD缓慢复发。上皮附着障碍眼睛同时饲养,并相对较快地重复。被证明PTK是所有6个角膜疾病类别的成功疗法。 PTK后疾病复发在疾病中不同,外科医生应认识到PTK手术后的不同疾病复发率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号